Inveready Takes Control of Chemistry CRO Enantia — Inveready

Enantia, a well-established Contract Research Organization (CRO) with over 20 years of experience in chemistry services, has been fully acquired by INVACO, a company controlled by the Inveready Biotech IV venture capital fund, which specializes in life sciences and healthcare. The transaction also includes participation from Enantia’s management team in the shareholding structure.